CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function

BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells

(2009) P. Ramirez et al.   BLOOD

Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization

(2009) M. J. Christopher et al.   BLOOD

Parsing the niche code: the molecular mechanisms governing hematopoietic stem cell adhesion and differentiation

(2009) E. C. Forsberg et al.   HAEMATOLOGICA

Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab

(2009) Werner Wenning et al.   NEW ENGLAND JOURNAL OF MEDICINE

Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy

(2009) Hans Lindå et al.   NEW ENGLAND JOURNAL OF MEDICINE

About multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors

(2008) C. Vuaillat et al.   BLOOD

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans

(2008) F. Zohren et al.   BLOOD

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab

(2008) H. Bonig et al.   BLOOD

CXCR4 is required for the quiescence of primitive hematopoietic cells

(2008) Yuchun Nie et al.   JOURNAL OF EXPERIMENTAL MEDICINE